Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Holding PTCT?
Track your performance easily
PTCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$23.58 - $54.16
Previous Close$49.86
Volume596.83K
Average Volume (3M)816.72K
Market Cap
$3.88B
Enterprise Value$3.27B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$400.20M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Feb 25, 2025EPS Estimate
-$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.94
Shares Outstanding77,125,143
10 Day Avg. Volume1,132,781
30 Day Avg. Volume816,721
Standard Deviation0.13
R-Squared0.06
Alpha0.00063
Financial Highlights & Ratios
Price to Book (P/B)-3.65
Price to Sales (P/S)4.31
Price to Cash Flow (P/CF)-12.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda-18.38
Forecast
1Y Price Target
$55.00Price Target Upside13.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
PTC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityManagement noted that with cash from the PRV and PTC518 deal, it does not see a need to raise additional capital to reach cash flow breakeven or beyond.
Growth PotentialPTC believes the agreement with Novartis will enhance and accelerate the process for PTC518 in Huntington's disease.
Strategic PartnershipThe recently announced Novartis collaboration for PTC518 boosts the company’s liquidity position to ~$2B.
Bears Say
Clinical TrialsPTC Therapeutics announced the Phase II CardinALS clinical trial of utreloxastat in ALS failed to meet its primary endpoint of slowing disease progression.
Financial PerformancePTC Therapeutics' expected share price return is projected to be negative.
Regulatory ChallengesThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has maintained their negative opinion on the renewal of the marketing authorization of Translarna, which should be ratified by the European Commission and will ultimately result in Translarna being withdrawn from the EU market.
---
Ownership Overview
1.15% Insiders
29.27% Mutual Funds
38.69% Other Institutional Investors
13.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $23.58 and its highest was $54.16 in the past 12 months.
What is PTC Therapeutics’s market cap?
Currently, no data Available
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 80 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.39 earnings per share for the quarter, beating the consensus estimate of -$1.521 by $0.131.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -$0.79.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 77,125,145 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.39 in its last earnings report, beating expectations of -$1.521. Following the earnings report the stock price went up 3.073%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Among the largest hedge funds holding PTC Therapeutics’s share is Blackstone Inc.. It holds PTC Therapeutics’s shares valued at 41M.
---
PTC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$55.00 (13.64% Upside)
$55.00 (13.64% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 21.6%
Last 30 Days ▲ 48.4%
Last 30 Days ▲ 48.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.22%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q3 2024
0:00 / 0:00
---
PTCT Stock 12 Month Forecast
Average Price Target
$55.00
▲(13.64% Upside)
Technical Analysis
Sarepta Therapeutics
―
Vertex Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+38.09%
reiterated a buy rating 4 days ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +38.09% per trade.
---